Aharon Yaari, president and CEO (API division) of Teva group, said, "India is an important part in our development programmes, and we are looking at collaborations with Indian companies in clinical programmes and biotechnology."
He was speaking after inaugurating Teva's research and development centre in Noida - Teva's third biggest in the world after Israel and Hungary.
"The alliance or partnerships with Indian companies will be in new areas apart from our traditional stronghold of CNS drugs," Lazer Bezdin, country manager (India) of Teva, said.
He also said the company would more than double its R&D strength in India to about 120 in three years.
Teva has made an initial investment of $4 million at the Noida facility. The company has also added a sixth API manufacturing unit at Gajrola (Haryana) with an approximate investment of $30 million.